Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, the Company has also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided below.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar exp
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... TORONTO , Feb. 27, 2015  Bionik Laboratories ... (the "Company"), announced today that it acquired Bionik Laboratories, ... Laboratories"), and completed the sale to qualified accredited investors ... for aggregate gross proceeds of approximately $6.2 million. Shares ... quoted on the OTC Markets under the symbol "DWTPD" ...
(Date:2/26/2015)... , February 27, 2015 ... 2014 market research report to its store. This ... Ulcers, therapeutic pipeline. The report "Corneal ... the therapeutic development for Corneal Ulcers. Corneal Ulcers ... includes bacterial infections, viral infections & fungal infections. ...
(Date:2/26/2015)...  IRIDEX Corporation (NASDAQ: IRIX ) today announced ... 2014 financial results after the market closes on Thursday, ... Company will host a conference call with the investment community ... March 5, 2015 to discuss the results of the ... access the live conference call via telephone by dialing (877) ...
Breaking Medicine Technology:Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... Group (MRG), the global authority on medical technology ... research data for multiple geographies, including the US, ... MRG,s peripheral vascular reports cover minimally invasive ... stenting, percutaneous transluminal balloon angioplasty, and synthetic surgical ...
... RO, ROG; OTCQX: RHHBY) and study investigators from Harvard ... the PROTECT ( Pr o-BNP O utpatient ... T herapy) trial, a strategy of NT-proBNP guided heart ... in total cardiovascular events, the primary composite endpoint of ...
Cached Medicine Technology:New Peripheral Vascular Device Market Research Data Covering Multiple Geographies Released by Millennium Research Group 2NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events 2NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events 3
(Date:2/27/2015)... (PRWEB) February 27, 2015 Royal River Natural ... reports a new study that found adults who got the ... type 2 diabetes compared to those who got the least ... sugar levels. , The report is part of the March ... which Royal River Natural Foods publishes free each month for ...
(Date:2/27/2015)... February 27, 2015 On February 24 2015, ... Liquid Botox ,” that details the development of RT001, ... working its way through FDA trials. For those afraid of ... is very attractive. Of course, if the drug ultimately gets ... a physician’s office. (see: goo.gl/PQvQwk) , “As the article notes, ...
(Date:2/27/2015)... Winter is here, and with it comes ... to snow and ice can be harmful on a dog’s ... The Puppy Store is ready to help pet owners know ... in the winter time. , Ice melts can lead to ... symptoms. Ingestion of ice melt products may cause depression, loss ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Victorian Hotel ... deals for couples who wanted to spend the auspicious ... opportunity to get a jump on Valentine’s Day with ... stay in one of their luxurious rooms. , ... 13, inviting guests for a mouthwatering 3 course meal ...
(Date:2/27/2015)... February 27, 2015 Mediaplanet today announces ... Health,” a campaign that aims to bring blood health ... care conversation. The stories in this edition go beyond ... of clinical care, hard-hitting advocacy, research and technological strides ... According the American Cancer Society, approximately every 3 ...
Breaking Medicine News(10 mins):Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2Health News:Is Topical Botox the Next Big Thing? 2Health News:The Puppy Store Helps Dogs Prepare for Harsh Winter Conditions 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2
... a small,molecule pharmaceutical company focused on the discovery ... to the eicosanoid pathway,today announced the appointment of ... Dr. Raizon-Ounis brings 20 years of pharmaceutical experience ... & licensing executive with,Roche Palo Alto. She began ...
... 1, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the,global ... Q3 2007 Financial Highlights - Product sales up 41% ... $608.7 million; - Net cash provided by operating activities ... growth now expected to be at least 30% (Q2 guidance: ...
... those with Lou Gehrig,s disease , , THURSDAY, Nov. ... antibiotic minocycline against amyotrophic lateral sclerosis -- Lou ... taking the drug had a significantly accelerated decline ... question plans to try minocycline against other neurodegenerative ...
... Less than a Month, SAN DIEGO, Nov. ... premier certification, education and training organization,recently released results ... for older adults; proving that it works and ... the goal of the study to,encourage older adults ...
... Walk ... Distance (p<0.0006), Conference Call to be ... SILVER SPRING, Md., Nov. 1 United,Therapeutics Corporation (Nasdaq: UTHR ... of their TRIUMPH-1 Phase 3,trial of Viveta, an inhaled formulation of ...
... - Fourth-quarter earnings per share from continuing operations increased ... 15% to 98 cents - ... specified items, increased 15% to ... operations, excluding specified items, to increase 10%-12%, ...
Cached Medicine News:Health News:Amira Pharmaceuticals Appoints First Vice President of Development 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 31Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 32Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 33Health News:Study Shows Antibiotic Harms ALS Patients 2Health News:Exclusive American Council on Exercise (ACE) Research Study Proves Functional Fitness Really Works 2
Chase micro-hemocrit tubes are manufactured from soda lime glass, packed in plastic vials with reclosable snap-lock caps to maintain cleanliness....
Hemato-clad Hematocrit Tubes combine the precision of glass with the safety provided by a Mylar® overwrap. Now you can give your laboratory staff safety with no compromise in accuracy....
... capillary tubes help protect healthcare workers from ... common medical procedures. Each BD plastic-coated micro-hematocrit ... so thin that it does not interfere ... inspection of the sample. The mylar film ...
... In the Innova™ 4100, the ... X-ray system for angiographic imaging, ... piece, non tiled Digital Detector ... reliably provide high resolution imaging ...
Medicine Products: